---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-121828"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:55:15.403635+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# VYNE Therapeutics to merge with Yarrow Bioscience; Yarrow stockholders to own ~97% of combined company

## Summary
- Pro forma ownership: pre-Merger Yarrow stockholders ~97%, VYNE stockholders ~3%.
- Pre-Closing Dividend of ~$14.5M to $16.5M to VYNE stockholders prior to close.
- Two concurrent financings: Yarrow Series A preferred ~$100M and Pre-Closing PIPE ~$100M.
- Expected close Q2 2026; post-close board and officers designated by Yarrow.

## SEC filing metadata
- accession: 0001104659-25-121828
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465925121828/0001104659-25-121828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465925121828/tm2533624d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-121828
- JSON: https://secwatch.observer/filing/0001104659-25-121828.json
- Plain text: https://secwatch.observer/filing/0001104659-25-121828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.